89 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/631099/mercks-keytruda-wins-eu-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-631099 Nov 21, 2019 - Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.
Armstrong World Industries acquires MRK Industries https://seekingalpha.com/news/3521942-armstrong-world-industries-acquires-mrk-industries?source=feed_news_all Nov 25, 2019 - Armstrong World Industries (NYSE:AWI) has completed the acquisition of MRK Industries, Inc. This further advances AWI’s strategy to sell into more spaces and sell more into every space by aggressively
Top Research Reports for Merck, Eli Lilly & Charter Communications http://www.zacks.com/research-daily/643445/top-research-reports-for-merck-eli-lilly-charter-communications?cid=CS-ZC-FT-research_daily-643445 Nov 27, 2019 - Top Research Reports for Merck, Eli Lilly & Charter Communications
Here's Why Merck's (MRK) Shares Are Up This Year http://www.zacks.com/stock/news/644873/heres-why-mercks-mrk-shares-are-up-this-year?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-644873 Nov 28, 2019 - Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.
Seattle Genetics, Astellas Tie Up With Merck for Cancer Study http://www.zacks.com/stock/news/652595/seattle-genetics-astellas-tie-up-with-merck-for-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-652595 Dec 03, 2019 - Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.
Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised) http://www.zacks.com/stock/news/653603/pfizer-astellas-xtandi-gets-nod-in-china-for-prostate-cancer-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-653603 Dec 04, 2019 - Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).
Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD http://www.zacks.com/stock/news/655863/bristol-myers-orencia-gets-breakthrough-therapy-tag-for-gvhd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-655863 Dec 05, 2019 - The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 9, 2019: MRK, PCG, M, DPLO, CHWY http://feeds.benzinga.com/~r/benzinga/~3/yu80-dB5jng/benzinga-pros-top-5-stocks-to-watch-for-mon-dec-9-2019-mrk-pcg-m-dplo-chwy Dec 09, 2019 -

Benzinga Pro's Stocks To Watch For Monday

Merck (MRK) - Reported it will purchase ArQule (ARQL) in a deal valued at $2.7 billion. The purchase price for ArQule was $20/share in cash. ArQule shares

read more

Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar http://www.zacks.com/stock/news/661958/amgen-gets-fda-approval-for-jj-mercks-remicade-biosimilar?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-661958 Dec 09, 2019 - FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.
Bristol-Myers' (BMY) Lymphoma Drug Meets Goals in Key Study http://www.zacks.com/stock/news/662000/bristol-myers-bmy-lymphoma-drug-meets-goals-in-key-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-662000 Dec 09, 2019 - Bristol-Myers' (BMY) TRANSCEND NHL 001 study on CAR T-cell therapy drug meets endpoints.

Pages: 123456...9

Page 1>